01
Strategic Uncertainty
High-fidelity “Friction Forecasts” predict shifts in prescription volume and patient persistence 3 to 6 months in advance.
- 3–6 mo horizon
- Persistence
- Rx volume
The “Future” · The Oracle & Predictive Forecasting
Own the
future.
Before it happens.
Strategic Alpha through 96% predictive accuracy. The Oracle for the Global Top 20.
Targeting
Chief Scientific Officers · Global Brand Leads · Portfolio Strategists
Vanguard · Oracle Console
Forecast
Friction · Oncology 2L+
Persistence drop forecast — T+14 wk
+96.2%
Sentiment · Cardiometabolic
Side-effect narrative shift incoming
+94.1%
Access · Immunology
Reimbursement wall — EU5, T+19 wk
+97.0%
Friction Forecast · 24 wk horizon
The Vision
The Vanguard Oracle represents a transition from data utility to a Strategic Monopoly. Reserved exclusively for the elite tier of global healthcare leaders, this platform is designed for C-suite visionaries who cannot afford to be surprised by the market. By identifying “Micro-Trends” before they manifest in official sales data, we offer the exclusive right to see the future of a therapeutic market.
“Own the future. Before it happens.”
What Vanguard Solves
Three forecasts,
priced as strategic monopoly.
Reserved for the C-suite tier that cannot afford to be surprised by the market.
02
High-Stakes Risk Mitigation
Maintain a 96% predictive accuracy threshold to validate billion-pound R&D investments and portfolio decisions.
- 96% accuracy
- R&D validation
- Portfolio
03
Market Dominance
Secure “Vertical Lock-outs” to ensure your firm is the only one in your therapeutic area with access to our live predictive sentiment. Includes complete therapeutic vertical lock-out with rolling 30-day market exclusivity auctions to guarantee asymmetric competitive alpha.
- Vertical lock-out
- One firm · one TA
- Exclusive feed
The Forecasting Layer
Forecast the friction. Months before the market feels it.
Forecast Heat Map
Indication × region · T+24 wk
01 · Forecast
Micro-Trend Detection
Identify Micro-Trends before they manifest in official sales data — the geography of stalled uptake, rendered 3 to 6 months before the print.
02 · Validate
96% Accuracy Threshold
A 96% predictive accuracy threshold, maintained across oncology, cardiometabolic, immunology and rare disease — the bar required to validate billion-pound R&D and portfolio decisions.
While the Vanguard Oracle platform maintains a high-fidelity predictive accuracy threshold of 96%, it is designed as a strategic augment; all critical commercial and clinical decisions should be triangulated using a variety of internal and external data sources to ensure a comprehensive market perspective.
Accuracy Ledger
Trailing 24 mo · audited
Oncology
97.1%
Cardiometabolic
95.6%
Immunology
96.4%
Rare Disease
95.9%
The Vanguard Advantage
Three instruments
Three instruments
of dominance.
Vanguard extends Pharmatica’s analyst infrastructure into a predictive operating surface — reserved for the firms whose decisions move billions.
Kingmaker status
Vertical exclusivity, by indication.
Bespoke intelligence on specific high-stakes indication logic and sequence models — granted to one firm per therapeutic area for the duration of the engagement.
Predictive friction
See the wall before you hit it.
Identify side-effect sentiment shifts or reimbursement walls months before they impact the bottom line — actionable while the narrative is still movable.
Scientific Council
Direct strategic advisory.
Exclusive access to Pharmatica’s Scientific Council to interpret AI forecasts against your specific drug pipelines and portfolio commitments.
Reserved access
One firm. One indication. One Oracle.
Reserved for the elite tier of global healthcare leaders
- Chief Scientific Officers
- Global Brand Leads
- Portfolio Strategists
Reserved for the Global Top 20
Own the future.
Start with Vanguard.
Audiences are private, conducted by a Pharmatica analyst lead and the Scientific Council, tailored to your therapeutic and portfolio priorities.
A Pharmatica product
